Clinical Trials Browser

Phase 1/2 × lirilumab × 1 year × Clear all

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

Neoplasms

NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Phase 1/2 Completed

320 enrolled 35 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma